Structured around development of a sustained-release drug-delivery system designed to tackle achieving delivery of therapeutic agents that are notoriously hard-to-deliver. The firm is anchored in a patented platform technology -- originally developed at Albert Einstein College of Medicine -- that leverages hydrogel-derived nanoparticles to deliver in a sustained and controlled manner therapeutic agents through topical administration. The technology enables a product concept called the Patchless Patch, an response to a lidocaine patch. If effective, the system could enabling the healthcare industry to harness the therapeutic potential across a variety of applications.
